Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2025 Earnings Call Transcript March 19, 2026 Taysha Gene Therapies, Inc. beats earnings expectations. Reported EPS is $-0.08711, expectations were ...

Joining me on today’s call are Sean Nolan, Taysha Gene Therapies, Inc.'s Chief Executive Officer; Sukumar Nagendran, ...

By any measure, 2025 was a landmark year for Cibus, Inc., not because of any single headline, but because of a convergence of key themes that are shaping the trajectory of the gene editing industry.

Learn about comparative gene expression studies in Alzheimer's disease and other conditions in Mayo Clinic's Precision Medicine in Neurodegeneration Lab.

I'd like to thank you for taking time to join us for Cibus' Fourth Quarter 2025 Financial Results and Business ...

Cibus, Inc. (NASDAQ:CBUS) Q4 2025 Earnings Call Transcript March 17, 2026 Cibus, Inc. beats earnings expectations. Reported EPS is $-0.06837, expectations were $-0.3525. Operator: Thank you for your ...

A newly released publication examines how deuterium concentration may influence gene activity in lung cancer cells. The study explores how shifts in this ...

Greetings, and welcome to the ClearPoint Neuro, Inc. Fourth Quarter and Full Year 2025 Financial Results Conference Call. [Operator Instructions] As a reminder, this con ...

The authors conclude that mRNA vaccines “induce a gene-altering [mode of action], reprogramming host expression programs” that go far beyond inflammatory responses to Spike protein. Effects include ...

They aren’t exactly glamorous, but naked mole rats have genes that could mean feeling younger and living longer.

Good afternoon, and thank you for joining us for BioLife Solutions, Inc.'s fourth quarter and full year 2025 conference call.